Enter multiple symbols separated by commas

Amgen to Buy Kidney Disease Drug Company for $420 Million

Amgen said on Monday it has agreed to buy privately held Ilypsa, which is developing a drug for chronic kidney disease, for $420 million in cash.

Directors from each company and shareholders of Ilypsa have approved the proposed acquisition. The deal should close by the third quarter of 2007, the companies said.

Santa Clara, California-based Ilypsa's lead experimental drug candidate is ILY101, which is designed to treat hyperphosphatemia in chronic kidney disease in patients on hemodialysis.

Many large pharmaceutical companies are faced with looming patent expirations on drugs that bring in the majority of their sales and are buying smaller firms with promising products in a bid to secure future revenue.

Amgen's key products include anemia drugs Aranesp and Epogen, which are the focus of recent safety concerns.

Shares in Amgen closed down 3 cents to $56.91 on the Nasdaq, down about 18% from a year ago.

Contact U.S. News


    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.

Don't Miss

  • Members of the New Horizons science team react to seeing the spacecraft's last and sharpest image of Pluto before closest approach later in the day at the Johns Hopkins University Applied Physics Laboratory (APL) in Laurel, Maryland July 14, 2015.More than nine years after its launch, a U.S. spacecraft sailed past Pluto on Tuesday, capping a 3 billion mile (4.88 billion km) journey to the solar system's farthest reaches, NASA said.

    The New Horizons Pluto flyby mission set records for NASA's social media and web metrics——but why do we care so much?

  • Ferrari 488 Spider

    Ferrari's new 488 Spider will have a V-8 turbo engine and a retractable hard-top roof that lowers in just 14 seconds.

  • Thomas Lee

    This year's flat market is reminiscent of 1904, says Thomas Lee of Fundstrat Global Advisors in an interview with Amanda Drury.

U.S. Video